Nirsevimab Immunization to Prevent Pediatric RSV Hospitalizations - Summary - MDSpire

Nirsevimab Immunization to Prevent Pediatric RSV Hospitalizations

  • By

  • Federica Attaianese

  • Giulia Carreras

  • Sandra Trapani

  • Ilaria Alberti

  • Maurizio Aricò

  • Marina Attanasi

  • Giulia Bertolucci

  • Silvia Bressan

  • Désirée Caselli

  • Veronica Casotto

  • Salvatore Cazzato

  • Francesco Chiarelli

  • Enrico Felici

  • Anna Frusciante

  • Maria Antonia Galeone

  • Silvia Garazzino

  • Antonietta Giannattasio

  • Eloisa Gitto

  • Antonio Guerriero

  • Fiorentina Guida

  • Giovanna Iudica

  • Marcello Lanari

  • Claudia Mandato

  • Alice Manzini

  • Gaia Martelli

  • Gregorio Paolo Milani

  • Maria Moriondo

  • Lucia Dora Notarangelo

  • Felice Nunziata

  • Roberta Pellegrino

  • Diego Peroni

  • Emanuela Piccotti

  • Eduardo Ponticiello

  • Silvia Ricci

  • Immacolata Rulli

  • Fabio Savoia

  • Erika Silvestro

  • Antonella Sisto

  • Federica Soro

  • Stefania Tonetto

  • Alessandro Zago

  • Carlo Dani

  • Chiara Azzari

  • Giuseppe Indolfi

  • July 1, 2026

  • 0 min

Share

Objective:

To evaluate the real-world cost-effectiveness of nirsevimab in preventing RSV-associated hospitalizations based on observed hospitalization outcomes across 19 Italian pediatric hospitals.

Approach:
  • Study Design: Multicenter, observational, cost-effectiveness analysis using anonymized hospital administrative data.
  • Data Collection: RSV-related hospitalizations identified using ICD-9-CM codes from October 1, 2022, to March 31, 2025, excluding the COVID-19 pandemic period.
  • Cost Assessment: Costs evaluated from the perspective of the Italian National Health Service, including hospitalization costs and immunization program costs.
  • Statistical Analysis: Poisson regression models used to estimate expected hospitalizations without immunization; cost-effectiveness ratio calculated as incremental costs divided by hospitalizations averted.
Key Findings:
  • Nirsevimab demonstrated high efficacy in reducing RSV-related hospitalizations.
  • The cost of nirsevimab was €230 per dose during the 2024 to 2025 season.
  • Substantial heterogeneity in immunization campaign implementation across regions, affecting the overall effectiveness.
Interpretation:

The study provides evidence on the cost-effectiveness of nirsevimab for RSV prevention, highlighting variability in implementation strategies.

Limitations:
  • Real-world cost-effectiveness evidence is limited to a specific context in Italy, which may not be generalizable.
  • Projected economic outcomes may differ from actual implementation due to variability in hospitalization burden and immunization timing.
Conclusion:

The study aims to inform immunization strategies for RSV prevention in pediatric populations.

Original Source(s)

Nirsevimab Immunization to Prevent Pediatric RSV Hospitalizations

  • by Federica Attaianese, Giulia Carreras, Sandra Trapani, Ilaria Alberti, Maurizio Aricò, Marina Attanasi, Giulia Bertolucci, Silvia Bressan, Désirée Caselli, Veronica Casotto, Salvatore Cazzato, Francesco Chiarelli, Enrico Felici, Anna Frusciante, Maria Antonia Galeone, Silvia Garazzino, Antonietta Giannattasio, Eloisa Gitto, Antonio Guerriero, Fiorentina Guida, Giovanna Iudica, Marcello Lanari, Claudia Mandato, Alice Manzini, Gaia Martelli, Gregorio Paolo Milani, Maria Moriondo, Lucia Dora Notarangelo, Felice Nunziata, Roberta Pellegrino, Diego Peroni, Emanuela Piccotti, Eduardo Ponticiello, Silvia Ricci, Immacolata Rulli, Fabio Savoia, Erika Silvestro, Antonella Sisto, Federica Soro, Stefania Tonetto, Alessandro Zago, Carlo Dani, Chiara Azzari, Giuseppe Indolfi

  • July 1, 2026

Related Content

Case Report: Surgical management of thoracic chondrodysplasia in children: complete mobile thoracic replacement

Alanine aminotransferase elevation in hospitalized children with infectious mononucleosis: independent associations with Epstein–Barr virus DNA load, age, and sex

Case Report: Pediatric MOG/NMDAR overlap syndrome with delayed cortical MRI evolution and incidental venous sinus hypoplasia